Δcps1 vaccine protects dogs against experimentally induced coccidioidomycosis.

Autor: Shubitz LF; Valley Fever Center for Excellence, The University of Arizona, 1656 E Mabel St, PO Box 245215, Tucson, AZ 85724, United States. Electronic address: Lfshubit@email.arizona.edu., Robb EJ; Anivive Lifesciences, LLC, 3250 Airflite Way STE 400, Long Beach, CA 90807, United States., Powell DA; Valley Fever Center for Excellence, The University of Arizona, 1656 E Mabel St, PO Box 245215, Tucson, AZ 85724, United States; Department of Immunobiology, The University of Arizona, 1656 E Mabel St, PO Box 245221, Tucson, AZ 85724, United States., Bowen RA; College of Veterinary Medicine and Biomedical Sciences, Colorado State University, 1601 Campus Delivery, Ft. Collins, CO 80523, United States., Bosco-Lauth A; College of Veterinary Medicine and Biomedical Sciences, Colorado State University, 1601 Campus Delivery, Ft. Collins, CO 80523, United States., Hartwig A; College of Veterinary Medicine and Biomedical Sciences, Colorado State University, 1601 Campus Delivery, Ft. Collins, CO 80523, United States., Porter SM; College of Veterinary Medicine and Biomedical Sciences, Colorado State University, 1601 Campus Delivery, Ft. Collins, CO 80523, United States., Trinh H; Valley Fever Center for Excellence, The University of Arizona, 1656 E Mabel St, PO Box 245215, Tucson, AZ 85724, United States., Moale H; Valley Fever Center for Excellence, The University of Arizona, 1656 E Mabel St, PO Box 245215, Tucson, AZ 85724, United States., Bielefeldt-Ohmann H; Chemistry and Molecular Biosciences, University of Queensland, St Lucia, Qld 4072, Australia., Hoskinson J; Hoskinson, DACVR, 5001 Foothills Drive, Berthoud, CO, 80513, United States., Orbach MJ; Valley Fever Center for Excellence, The University of Arizona, 1656 E Mabel St, PO Box 245215, Tucson, AZ 85724, United States; School of Plant Sciences, The University of Arizona, 1140 E South Campus Drive, PO Box 210036 303 Forbes Bldg, Tucson, AZ 85721, United States., Frelinger JA; Valley Fever Center for Excellence, The University of Arizona, 1656 E Mabel St, PO Box 245215, Tucson, AZ 85724, United States., Galgiani JN; Valley Fever Center for Excellence, The University of Arizona, 1656 E Mabel St, PO Box 245215, Tucson, AZ 85724, United States; Department of Medicine, The University of Arizona, 1501 N Campbell Ave PO Box 245035, Tucson, AZ 85724, United States.
Jazyk: angličtina
Zdroj: Vaccine [Vaccine] 2021 Nov 16; Vol. 39 (47), pp. 6894-6901. Date of Electronic Publication: 2021 Oct 23.
DOI: 10.1016/j.vaccine.2021.10.029
Abstrakt: Coccidioidomycosis is a significant health problem of dogs and humans in endemic regions, especially California and Arizona in the U.S. Both species would greatly benefit from a vaccine to prevent this disease. A live avirulent vaccine candidate, Δcps1, was tested for tolerability and efficacy to prevent pulmonary coccidioidomycosis in a canine challenge model. Vaccine injection-site reactions were transient and there were no systemic effects observed. Six of seven vaccine sites tested and all draining lymph nodes were sterile post-vaccination. Following infection with Coccidioides posadasii, strain Silveira, arthroconidia into the lungs, dogs given primary and booster vaccinations had significantly reduced lung fungal burdens (P = 0.0003) and composite disease scores (P = 0.0002) compared to unvaccinated dogs. Dogs vaccinated once had fungal burdens intermediate between those given two doses or none, but disease scores were not significantly different from unvaccinated (P = 0.675). Δcps1 was well-tolerated in the dogs and it afforded a high level of protection when given as prime and boost. These results drive the Δcps1 vaccine toward a licensed veterinary vaccine and support continued development of this vaccine to prevent coccidioidomycosis in humans.
Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [John N Galgiani reports financial support was provided by National Institutes of Health. Edward Robb reports financial support and equipment, drugs, or supplies were provided by Anivive Life Sciences, LLC. Edward Robb reports a relationship with Anivive Lifesciences, LLC that includes: employment.. Lisa Shubitz has patent #Fungal lmmunogens and Related Materials and Methods WO2014164843-A1 issued to Arizona Board of Regents. Marc Orbach has patent #Fungal lmmunogens and Related Materials and Methods WO2014164843-A1 issued to Arizona Board of Regents.].
(Copyright © 2021. Published by Elsevier Ltd.)
Databáze: MEDLINE
Externí odkaz: